AxoGen, Inc. (NASDAQ:AXGN - Get Free Report) insider Erick Wayne Devinney sold 15,111 shares of AxoGen stock in a transaction that occurred on Wednesday, March 19th. The stock was sold at an average price of $17.50, for a total value of $264,442.50. Following the completion of the sale, the insider now owns 217,762 shares in the company, valued at approximately $3,810,835. This represents a 6.49 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.
AxoGen Stock Performance
Shares of NASDAQ AXGN opened at $17.90 on Thursday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.47 and a current ratio of 3.74. The company has a market cap of $793.76 million, a P/E ratio of -55.94 and a beta of 1.02. AxoGen, Inc. has a 52-week low of $5.55 and a 52-week high of $21.00. The firm's fifty day moving average is $18.19 and its two-hundred day moving average is $15.58.
Institutional Trading of AxoGen
A number of large investors have recently added to or reduced their stakes in the company. Principal Financial Group Inc. bought a new position in shares of AxoGen in the 3rd quarter valued at about $207,000. Los Angeles Capital Management LLC purchased a new stake in shares of AxoGen during the third quarter valued at $279,000. Oppenheimer & Co. Inc. purchased a new position in shares of AxoGen during the third quarter worth approximately $156,000. Quest Partners LLC increased its holdings in AxoGen by 23,066.7% during the 3rd quarter. Quest Partners LLC now owns 2,085 shares of the medical equipment provider's stock worth $29,000 after purchasing an additional 2,076 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of AxoGen by 66.3% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 308,686 shares of the medical equipment provider's stock valued at $4,328,000 after acquiring an additional 123,118 shares in the last quarter. Institutional investors own 80.29% of the company's stock.
Wall Street Analysts Forecast Growth
AXGN has been the topic of several analyst reports. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $24.00 price objective on shares of AxoGen in a research report on Wednesday, March 5th. Canaccord Genuity Group increased their price target on shares of AxoGen from $22.00 to $26.00 and gave the stock a "buy" rating in a research report on Wednesday, February 26th. Finally, Lake Street Capital began coverage on AxoGen in a research note on Monday. They set a "buy" rating and a $30.00 price objective for the company. Six analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $22.60.
Read Our Latest Report on AxoGen
About AxoGen
(
Get Free Report)
AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
